• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    7/12/24 6:23:25 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email
    SC 13G/A 1 d813236dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 1 )

     

     

    Korro Bio, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    500946108

    (CUSIP Number)

    July 12, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 500946108     13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Bermuda

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     413,072

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     413,072

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     413,072

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.5%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    2


    CUSIP No. 500946108     13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities Advisors, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     413,072

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     413,072

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     413,072

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.5%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    3


    CUSIP No. 500946108     13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International S.C.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     413,072

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     413,072

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     413,072

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.5%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    4


    CUSIP No. 500946108     13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International Management S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     413,072

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     413,072

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     413,072

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.5%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    5


    CUSIP No. 500946108     13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal Group S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     413,072

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     413,072

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     413,072

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.5%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    6


    CUSIP No. 500946108     13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Westend S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     413,072

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     413,072

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     413,072

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.5%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    7


    CUSIP No. 500946108     13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Stichting Administratiekantoor Westend

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     413,072

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     413,072

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     413,072

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.5%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    8


    CUSIP No. 500946108     13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Mr. Amaury Wittouck

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Belgium

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     413,072

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     413,072

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     413,072

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.5%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    9


    Item 1(a).

    Name of Issuer:

    Korro Bio, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139

     

    Item 2(a).

    Name of Person Filing:

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship:

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Bermuda limited partnership

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iii) Artal International S.C.A. (“Artal International”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg limited partnership

    (iv) Artal International Management S.A. (“Artal International Management”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (v) Artal Group S.A. (“Artal Group”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vi) Westend S.A. (“Westend”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vii) Stichting Administratiekantoor Westend (the “Stichting”)

    Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

    Citizenship: Netherlands foundation

    (viii) Mr. Amaury Wittouck

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Belgium

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.001 par value per share (the “Shares”)

     

    Item 2(e).

    CUSIP Number:

    500946108

     

    10


    Item 3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    As of the date hereof, Invus Public Equities directly holds 413,072 Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares beneficially owned by Invus Public Equities. The Geneva branch of Artal International, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Artal International Management, as the managing partner of Artal International, controls Artal International and, accordingly, may be deemed to beneficially own the Shares that Artal International may be deemed to beneficially own. Artal Group, as the sole stockholder of Artal International Management, controls Artal International Management and, accordingly, may be deemed to beneficially own the Shares that Artal International Management may be deemed to beneficially own. Westend, as the parent company of Artal Group, controls Artal Group and, accordingly, may be deemed to beneficially own the Shares that Artal Group may be deemed to beneficially own. The Stichting, as the majority stockholder of Westend, controls Westend and, accordingly, may be deemed to beneficially own the Shares that Westend may be deemed to beneficially own. Mr. Wittouck, as the sole member of the board of the Stichting, controls the Stichting and, accordingly, may be deemed to beneficially own the Shares that the Stichting may be deemed to beneficially own.

    (b) Percent of class:

    As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on 9,272,987 Shares outstanding as of May 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 14, 2024.

    (c) Number of shares as to which Invus Public Equities, Invus PE Advisors, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck has:

    (i) Sole power to vote or to direct the vote:

    413,072

    (ii) Shared power to vote or to direct the vote:

    0

    (iii) Sole power to dispose or to direct the disposition of:

    413,072

    (iv) Shared power to dispose or to direct the disposition of:

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    11


    Item 8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    12


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 12, 2024

     

    INVUS PUBLIC EQUITIES, L.P.
    By:   INVUS PUBLIC EQUITIES ADVISORS, LLC, its general partner
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    INVUS PUBLIC EQUITIES ADVISORS, LLC
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    ARTAL INTERNATIONAL S.C.A.
    By:   ARTAL INTERNATIONAL MANAGEMENT S.A., its managing partner
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL INTERNATIONAL MANAGEMENT S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL GROUP S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Authorized Person


    WESTEND S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    STICHTING ADMINISTRATIEKANTOOR WESTEND
    By:  

    /s/ Amaury Wittouck

    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK

    /s/ Amaury Wittouck

    Get the next $KRRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    3/13/2026$23.00Mkt Perform → Outperform
    Raymond James
    2/17/2026Mkt Perform → Outperform
    William Blair
    1/29/2026$30.00Neutral → Overweight
    Piper Sandler
    1/29/2026$15.00Neutral → Buy
    Chardan Capital Markets
    1/29/2026$20.00Neutral → Buy
    H.C. Wainwright
    1/28/2026$21.00Neutral → Overweight
    Cantor Fitzgerald
    1/28/2026$22.00Perform → Outperform
    Oppenheimer
    11/13/2025$8.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on Decem

    3/12/26 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro to Present at the TD Cowen 46th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar's presentation will take place on Tuesday, March 3, 2026, at 11:10 a.m. ET. About Korro Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevale

    2/25/26 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro to Host Virtual Analyst Day on January 27, 2026

    - Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro management team, Bruce Scharschmidt, MD, hepatologist and former Chief Medical Officer of Hyperion Therapeutics, and Michelle Dinon, parent of a child impacted by a urea cycle disorder (UCD). Korro

    1/20/26 8:00:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sandell Scott D bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:15 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner New Enterprise Associates 17, L.P. bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:13 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Yang Rick bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:16 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    SEC Filings

    View All

    SEC Form 424B5 filed by Korro Bio Inc.

    424B5 - Korro Bio, Inc. (0001703647) (Filer)

    3/20/26 5:03:09 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Korro Bio Inc.

    S-3 - Korro Bio, Inc. (0001703647) (Filer)

    3/13/26 5:05:49 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Korro Bio Inc.

    10-K - Korro Bio, Inc. (0001703647) (Filer)

    3/12/26 4:12:03 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Behbahani Ali was granted 207,100 shares (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:10 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Sandell Scott D bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:15 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner New Enterprise Associates 17, L.P. bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:13 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Korro Bio upgraded by Raymond James with a new price target

    Raymond James upgraded Korro Bio from Mkt Perform to Outperform and set a new price target of $23.00

    3/13/26 8:41:33 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio upgraded by William Blair

    William Blair upgraded Korro Bio from Mkt Perform to Outperform

    2/17/26 7:51:08 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Korro Bio from Neutral to Overweight and set a new price target of $30.00

    1/29/26 6:58:39 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    View All

    Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    4/1/25 7:30:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    12/10/24 8:00:00 AM ET
    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

    - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

    11/12/24 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 7:54:42 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 3:04:22 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 12:21:08 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care